WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO), today reported publication of the initial Quell® study in the Journal of Pain Research. The paper is titled “Fixed-Site High-Frequency Transcutaneous Electrical Nerve Stimulation for Treatment of Chronic Low Back and Lower Extremity Pain.” It is available on-line at:
“Fixed-Site High-Frequency Transcutaneous Electrical Nerve Stimulation for Treatment of Chronic Low Back and Lower Extremity Pain.”
Journal of Pain Research - Quell Study
About Quell
Quell is FDA cleared and designed for the millions of people suffering from chronic pain. The advanced wearable technology delivers 100% drug free relief and is available without a prescription. Quell can be used during the day while active, and at night while sleeping. Quell gives users the option to start, stop, and adjust therapy discreetly via their smartphone. It also enables advanced sleep tracking. Quell is available at select healthcare professionals and retailers. To find a Quell retailer, visit the Store Locator at QuellRelief.com.
About NeuroMetrix
NeuroMetrix is an innovative healthcare company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com
